The murine Wand Steelloci encode the Kit receptor tyrosine kinase and its ligand, Steel factor, respectively. Loss of function mutations at either the Wor SI loci lead t o a variety of pleiotropic developmental defects, including mast cell deficiency and severe macrocytic anemia. In addition to these loss-of-function mutations, gain-of-function mutations in ckit, leading t o constitutive activation of the Kit receptor, have also been identified in both rodent and human mastocytomas. In this study, we have examined the transforming potential and biologic effects of a point mutation that results in substitution of the aspartic acid at codon 814 in the cytoplasmic kinase domain t o tyrosine (D814Y) by introducing either wild-type (Kit) or mutant (KDY) cDNA into an interleukin-3-dependent mast cell line IC2. Stimulation of cells expressing the wild-type Kit receptor (IC2/Kit) with Steel factor in vitro resulted in a short-term growth re-HE KIT RECEPTOR tyrosine kinase (RTK), along with T the receptors for colony-stimulating factor-1 (CSF-1 R) and platelet-derived growth factor (PDGFR), form a subfamily of receptors (the type 111 RTKs) that share both sequence similarity and overall organization. The members of this RTK subfamily all have five Ig-like motifs in their extracellular domain, a single transmembrane domain, and a cytoplasmic kinase domain that is divided by a lunase insert sequence into an ATP-binding region and a phosphotransferase domain.' Insight into the biologic function of the Kit RTK came with the discovery that Kit is encoded by the white spotting (W) locus on mouse chromosome S'. ' and that the Steel (SI) locus on chromosome 10 encodes the ligand for Kit (alternatively called Steel factor, stem cell factor, mast cell growth factor, or Kit liga~id).~~' Mutations at either the W or SI loci result in dominant white-spotting, severe macrocytic anemia, mast cell deficiency, sterility,"-'? abnormalities in intestinal pacemaker activity due to defects in the development of the interstitial cells of Cajal,'3.'4 and a learning and memory deficit." These pleiotropic abnormalities result from loss of function mutations that lead to the reduction or abolition of intrinsic tyrosine kinase activity either as a result of structural mutations in the kinase domain of the Kit receptor or cis-acting regulatory mutations that affect the levels of c-kit transcription in affected cell lin- eages,12.16-18 Activation of the wild-type Kit receptor by Steel factor in cells that express Kit results in a number of possible biologic responses, including proliferation, ") migration, adhesion, survival, and differentiation.?" The binding of Steel factor to the Kit RTK also initiates a cascade of intracellular events, including receptor dimerization and autophosphorylation at specific tyrosine residues.?".?' The phosphorylated Kit receptor, like other RTKs, then associates with and, in some cases, phosphorylates a subset of intracellular signaling molecules via the Src homology 2 (SH2) domains of these proteins.22~25 Thus, the developmental defects caused by lossof-function mutations at the Wlc-Kit locus reflect the importance of the intracellular signaling pathways that are initiated by the Kit receptor.
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In addition to these loss-of-function mutations, activating mutations in other RTKs have been described that result in constitutive signaling and the acquisition of transforming and tumorigenic ability. Such activating mutations have been previously described, eg, in both the CSF-1 and the neulcerbB2 In addition, we have previously reported that the Kit receptor is constitutively phosphorylated and activated in the mouse mastocytoma cell line This constitutive activation of Kit is due to a point mutation in the cytoplasmic kinase domain resulting in the substitution of tyrosine for aspartic acid at codon 814 (D814Y).2y~3" The KIT RTK is also constitutively activated in a human mast cell leukemia cell line HMC-1 and this activation is associated with two mutations in c-kit, one located at the equivalent aspartic acid residue in human KIT receptor as that observed in the mouse p8 15 cell line at codon 81 6 (D8 16V) and the other in the juxtamembrane domain (VS60G).31 Recently, the D8 16V mutation has also been identified in the mononuclear cells of mastocytosis patients with an associated myelodysplastic di~order.~'
To determine the biologic effects of the D814Y activating mutation on mast cells, we have introduced the wild-type and activated Kit receptor, via high-efficiency retrovirus vectors, into the mouse mast cell line IC2 that does not express any 3118 PIA0 AND BERNSTEIN endogenous Kit receptor. Expression of this activated Kit RTK in IC2 cells resulted in ligand-independent cell growth, conferred tumorigenic potential in syngeneic hosts, and induced the expression of various genes associated with mast cell differentiation. These studies show that this activating Kit mutation, first identified in mouse and human mastocytoma cell lines, confers quantitative and qualitative changes that are not observed in mast cells after activation of the wild-type Kit receptor by Steel factor.
MATERIALS AND METHODS
Site-directed mutagenesis. The D8 14Y substitution was created by overlap extension using the polymerase chain reaction (PCR). Two pairs of primers (KJt4: TATTGTGAACCTGCTTGGCGCN GCC AGATACATCAGGAAT/Kit I : AGCAGCAAAGCCTGTTGG-ACT) and pBluescript KS'-Kit containing the 3.7-kb mouse c-kit cDNA as a template were used for the first round of PCR. The two products were gel purified, and equal amounts were then used as templates for amplification with the Kit1 and Kit4 primers. The final PCR products were digested with the restriction enzymes Apa I and Aut 11. The resulting DNA fragment, which contained the D814Y substitution, was subcloned into pBluescript KS'-Kit. digested with Apa I and Aut 11, and named KDY.
Cells and growth conditions. The interleukin-3 (IL-3)-dependent immature mast cell line IC2 (generously provided by Dr Ichiro Yahara, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) was established from a long-term culture of DBA/2 mouse splenocytes in the presence of IL-3.'' The IC2 cells were cultured in IC2 mix (RPMI 1640 containing 10% bovine calf serum [BCS], 5 X I 0-5 molL P-mercaptoethenol [P-ME], and 1 % X63 cell supernatants as IL-3 source).
Construction of Kit rerrovirul vectors uitd generation c$ cell lines expressing Kir or Kit-DY. Various murine c-Kit cDNAs were subcloned into the LXSN retroviral vector. The LXSN-Kit and LXSN-KDY constructs were generated by first adding a Not I site to the multiple cloning site of the LXSN vector,'4 followed by cloning the Xho I-Not I Kit or KDY coding region fragments into Xhn I-Not Idigested LXSN DNA. The BOSC 23 ecotropic packaging cell line was transiently transfected by means of the Stratagene transfection kit (Stratagene, La Jolla. CA), with either LXSN, LXSN-Kit, or LXSN-KDY, as described.'5 Ten hours after transfection, fresh media was added. Viral supernatants containing virus were collected 48 hours later, filtered, and used to infect either NIH/3T3 cells (for titering) or IC2 cells. Infected 3T3 cells were selected by growth in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% BCS and 500 pg/mL G418 for 10 days. The viral titers were in the range of 2 to 5 x I@ colony-forming unitdml. IC2 cells were selected by growth in IC2 Mix containing 1% X63 supernant and 800 pg active G418/mL for 1 week. Pools of resistant cells were used for further studies.
To measure cell growth in suspension, cells ( IO5) were seeded in 96-well plates (Nunc, Inc., Naperville, 1L) and grown in IC2 Mix for 48 hours in the presence or absence of growth factors. After 48 hours, the cells were labeled with I pCi of ['HI thymidine per milliliter for 4 hours. Cells were harvested onto a filter paper (ICN Biomedicals, Inc, Horsham, PA) by a semiautomatic cell harvester (Skatron, Lier, Norway); the filter paper was then air-dried and subjected to liquid scintillation counting.
To measure the ability of the IC2 cells to form colonies in vitro, 1.5 x IO' cells in 0.5 mL of RPMI 1640 with 5% BCS and 0.8% methylcellulose, supplemented with either 1 % X63 supernatants as source of IL-3, 100 ng/mL m,SF, or no growth factor, were plated in 6-well plates (Nunc). Colonies were counted after 14 days.
IC2, ICuKit, and IC2/KDY cells ( Tiu"rigenicity assrty.
IO' ) were injected intraveneously (IV) into syngeneic DBA/2 mice. Two months later, the mice were killed and the livers were examincd for tumor foci. 
RESULTS

Retroviral-mediated transjer and expression of the Kit and
KDY receptor CDNAS in IC2 mast cells. To study the effects of the D814Y mutation in the Kit receptor on mast cells, we constructed retroviral vectors expressing either the wild-type or mutant forms of the Kit receptor, as described in the Materials and Methods. High titers of helper-free retroviral vector stocks were generated by transiently transfecting LXSN, LXSN-Kit, or LXSN-KDY DNAs into the ecotropic virus packaging cell line, BOSC 23. Viral supernatants were used to infect IC2 cells, an immature mast cell line. Forty-eight hours later, the infected cells were subjected to selection in G418 for 1 week. To eliminate clonal variation, pools of resistant cells derived from each infection, named IC2/Neo, IC2/Kit, and ICS/KDY, were used for further (Fig I) . Unlike bone marrow-derived mast cells, IC2 cells, as well as IC2 cells infected with the control neo vector (IC2/Neo), do not express the Kit receptor. In contrast, both IC2/Kit and IC2/KDY cells expressed high levels of the Kit receptor on their cell surface, with a somewhat higher expression of wild-type Kit in the pool of G41gR IC2/Kit cells. The Kit receptors on both IC2/ Kit and IC2/KDY cells bound FITC-conjugated Steel factor and were internalized at a similar rate upon ligand binding (data not shown). Moreover, the mutant KDY receptors isolated from control or Steel factor-stimulated cells were constitutively phosphorylated on identical tyrosine residues, consistent with the notion that this receptor is fully activated in the absence of ligand (data not shown).
The biologic consequences of expressing either Kit or KDY in IC2 cells were next examined by comparing the proliferative response of IC2/Neo, IC2/Kit, and IC2/KDY cells under different growth conditions. Both IC2/Neo and IC2/Kit cells were strictly dependent on IL-3 for their growth (Fig 2) . Expression of the wild-type Kit receptor in IC2 cells enabled these cells to proliferate in the presence of Steel factor in a concentration-dependent manner (data not shown). In contrast, IC2/KDY cells proliferated at the same rate in the absence of exogenous IL-3 or Steel factor (Fig 2) . Moreover, IC2/KDY cells were capable of long-term growth (more than 4 weeks; data not shown) in the absence of any exogenous growth factors, indicating that the expression of KDY enabled on IC2 cells to grow indefinitely in the absence of added growth factors.
KDY mediates IC2 cell transformation and tumorigenicioi. To determine whether ectopic expression of either the wild-KDY promotes ligrrncl-independelit cell growth. We next injected IC2/Neo, IC2/Kit, or IC2/KDY cells into syngeneic DBA/2 mice ( I O mice/cell line), as described in the Materials and Methods, to determine whether the KDY receptor could also confer tumorigenic potential on IC2 cells. Two months later, the mice were killed and examined for mastocytomas. All of the mice injected with IC2/KDY cells developed mastocytomas in the liver, whereas only 40% of the mice injected with IC2/Kit cells did so, with much fewer tumor nodules observed in the livers of these mice. No mice injected with IC2INeo cells developed tumors (Fig 4) . To determine whether these cells had also homed to a hematopoietic organ, bone marrow cells from the injected mice were cultured in IC2 mix without exogenous growth factors with a media change every 3 days. After 2 weeks of cultivation, only cells derived from the mice injected with IC21 KDY cells had grown into a homogeneous cell population, resembling the injected IC2/KDY cells (data not shown). Thus, expression of KDY in IC2 cells is sufficient to confer tumorigenicity on these cells, suggesting that the ability of P8 I5 mastocytoma cells that harbor the original KDY mutation to form tumors in syngeneic mice results, at least in part, from the activating D814Y mutation in the Kit receptor.
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Activation of the Kit receptor by its ligand Steel factor in bone marrow-derived mast cells (BMMC) results in the induction of mast cell differentiation, as judged by an increase in cell size, the
KDY promotes IC2 cell diyerentiation.
For personal use only. on April 13, 2017. by guest www.bloodjournal.org extent of granulation, transition from alcian blue'/safraninto alcian blue and safranin double-positive, and changes in the expression of various mast cell proteases3' To determine whether the activated KDY receptor might also mediate mast cell differentiation in the absence of ligand, we first examined the cell size, extent of granulation and alcian blue/ safranin staining of the infected IC2 cells. As shown in Fig  5A, ectopic expression of KDY in IC2 cells triggered dramatic changes in cell size and the extent of alcian blue' granulation; however, safranin staining remained negative. These morphologic alterations were measured by flow cytometry by examining forward (cell size) and side (granulation) scatter in cells expressing either the wild-type Kit or KDY receptor. As shown in Fig 5B, analysis of side light scatter clearly showed the effect of KDY expression on granulation content (Fig 5C) . In contrast, cells expressing the wild-type Kit receptor did not exhibit these changes in cell size and granulation (Fig 5A, B, and C) . Genetic, biologic, and expression analysis has shown that the Kit receptor and its ligand Steel factor are crucial for the development of mast cells. In addition, activation of the Kit signaling pathway by Steel factor in BMMC results in the induction of mast cell differentiati~n.~' To examine the patterns of gene expression in IC2 cells expressing Kit or KDY, we generated MMCP-4-, MMCP-5-, and MMCP-6-specific probes by RT-PCR, as described in the Materials and Methods. These probes were then used to detect MMCP-4, MMCP-5, and MMCP-6 transcripts in IC2/Neo, IC2/Kit, and IC2/KDY cells. MMCPJ transcripts were observed in all cell types tested, and the levels were not affected by expression of Kit or KDY (Fig 6) . MMCP-6 transcripts were expressed at low level in IC2 cells, and the level increased as the result of KDY expression (Fig 6) . MMCP-4 transcripts were not detectable in IC2/Neo or IC2/Kit cells, but were specifically and abundantly expressed in IC2/KDY cells ( Fig  6) .
DISCUSSION
Loss-of-function mutations at the W locus in mice affect hematopoiesis, gametogenesis, melonogenesis, neural crest migration, and the development of the interstitial cells of Cajal in the However, our understanding of gain-offunction mutations in c-kit and their role in the development of hematologic malignancies is limited. In this report, we have investigated the effects of the oncogenically activated allele of c-kit, D814Y, on the growth and neoplastic transformation of an immature mast cell line, IC2. Expression of the mutant KDY receptor in IC2 cells enabled these cells to proliferate in suspension and to form colonies in semisolid medium in a ligand-independent manner and to give rise to mastocytomas in syngeneic DBA/2 mice. These results indicate that the constitutively activated KDY receptor possesses transforming activity and that its expression is sufficient to confer tumorigenic potential on IC2 cells.
Although both IL-3 and Steel factor are capable of inducing proliferation and differentiation of bone marrow progenitor cells into mast cells (MC), the patterns of gene transcription induced by IL-3 and Steel factor are quite distinct. Mouse bone marrow cells cultured in medium containing IL-3 differentiate into morphologically immature MC that express transcripts encoding MMCP-5 and MMCP-6, but not MMCP-4. The latter gene encodes a protease expressed in terminally differentiated connective tissue-type MC (CTMC). However, after cultivation in the presence of Steel factor, mast cells express high levels of "As that encode mast cell carboxypeptidase A (MC-CPA), MMCP-4, MMCP-5, MMCP-6, and the high-affinity IgE receptor (FccRIa), a phenotype that is indistinguishable from that of For personal use only. on April 13, 2017. by guest www.bloodjournal.org From in vivo differentiated mouse CTMC. Moreover, cultivation in the presence of both IL-3 and Steel factor BMMC fails to express MMCP-4, suggesting that IL-3 acts as an antagonist to Steel factor-mediated mast cell differentiati~n.~~ We analyzed the effects of the wild-type and mutant Kit receptors on the differentiation of IC2 cells. The wild-type Kit receptor failed to induce expression of MMCP-4 and MMCP-6 in the presence of IL-3 and Steel factor. In contrast, the KDY receptor also induced IC2 cell differentiation even in the presence of IL-3, as determined by the appearance of morphologic changes and the induction of RNA transcripts A corresponding to the mast cell proteases MMCP-4 and MMCP-6. Together, these experiments suggest that the D8 14Y mutation not only results in ligand-independent Kit signaling but also results in changes in gene expression that is not seen in cells expressing the wild-type Kit receptor exposed to Steel factor. These observations raise the intriguing possibility that the D8 14Y mutation in KDY qualitatively affects the intracellular molecular events that lie downstream of Kit.
It is of interest to note that the D814Y mutation in KDY and the mutation described in the RET RTK in patients with B C ." Consistent with this conclusion, the MEN2B mutation has been shown to affect RET substrate specificity.""' The mutations in both and KDY change the consensus residue in this region from an RTK-type amino acid to an amino acid usually found at the identical position in nonreceptor tyrosine kinases (NRTKs)." RTKs normally associate with group 111 SH2 domain-containing proteins. In contrast, NRTKs interact with signaling molecules containing a group I SH2 domain. Thus, the mutant KDY receptor. such as the RET"''N2" receptor, may adapt the conformation of NRTKs rather than RTKs. Because RTKs and NRTKs interact with different signaling proteins, such conformational changes may cause an alteration in substrate specificity. Indeed, we have recently shown that the D8 14Y mutation markedly affects substrate specificities based on both the in vivo patterns of protein tyrosine phosphorylation and in vitro analysis of peptide substrate specificity (Piao et al, manuscript submitted).
In summary, we have shown that mutation in the cytoplasmic kinase domain of the Kit receptor that results in its constitutive activation leads to the induction of transformation and differentiation in the IC2 mast cell line. In contrast, the wild-type Kit receptor failed to support long-term proliferation or to induce differentiation of IC2 cells in the presence of Steel factor. These data provide biologic evidence that the mutant KDY receptor may deliver both quantitatively and qualitatively different signals to IC2 cells. Further clarification of the mechanism of activation of this activating mutation and identification of novel substrates that specifically interact with the KDY receptor would provide insight into the molecular mechanisms underlying malignant transformation by this oncogenic variant of the Kit RTK.
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